Ajanta Pharma Peer Comparison
NSE: AJANTPHARM | BSE: 532331
₹3,288.10
₹-31.60
(-0.95%)
As on 04-Nov-2026 12:59IST
Market cap
₹41,308 Cr
Revenue (TTM)
₹6,217 Cr
P/E Ratio
32.7
P/B Ratio
8.5
Div. Yield
0.8 %
Edit
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
41,308 | 1,14,184 | 1,03,051 | 42,700 | 4,31,065 |
Revenue (₹ Cr) |
6,217 | 33,097 | 15,379 | 4,159 | 61,631 |
Net Profit (₹ Cr) |
1,262.83 | 2,759.70 | 2,249.69 | 1,146.54 | 11,037.19 |
Net Margin (%) |
19.70 | 8.03 | 14.32 | 26.40 | 17.23 |
RoE (%) |
26.91 | 7.30 | 13.86 | 54.63 | 14.23 |
Price to Earnings |
32.71 | 40.78 | 45.95 | 37.24 | 39.31 |
Price-To-Book |
8.50 | 2.94 | 5.86 | 22.70 | 4.83 |
Income Statement (₹ Cr)
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Operating Revenue
|
6,216.60 | 33,097.40 | 15,378.58 | 4,158.57 | 61,630.92 |
|
Total Income
|
6,411.29 | 34,352.50 | 15,705.47 | 4,343.18 | 64,063.12 |
|
Total Expenditure
|
4,529.81 | 28,236.90 | 11,301.83 | 2,738.73 | 43,720.59 |
|
EBITDA
|
1,686.79 | 4,860.50 | 4,076.75 | 1,419.84 | 17,910.33 |
|
Depreciation
|
180.94 | 2,141.40 | 907.11 | 64.35 | 3,004.86 |
|
EBIT
|
1,505.85 | 2,719.10 | 3,169.64 | 1,355.49 | 14,905.47 |
|
Interest
|
12.88 | 450.40 | 513.87 | 3.26 | 338.59 |
|
Other Income
|
194.69 | 1,255.10 | 326.89 | 184.61 | 2,432.20 |
|
Exceptional Items
|
0.00 | 0.00 | -129.75 | 17.98 | -1,962.40 |
|
Profit before Tax
|
1,687.66 | 3,523.80 | 2,852.91 | 1,554.82 | 15,036.68 |
|
Provision for Tax
|
424.83 | 764.10 | 603.22 | 408.28 | 3,999.49 |
|
Profit after Tax
|
1,262.83 | 2,759.70 | 2,249.69 | 1,146.54 | 11,037.19 |
Liabilities (₹ Cr)
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4,858.27 | 38,807.00 | 17,582.22 | 1,881.05 | 89,279.88 |
|
Minority Interest
|
0.00 | 40.20 | -20.87 | 0.00 | -20.97 |
|
Non-Current Liabilities
|
224.20 | 3,074.90 | 5,214.33 | 281.75 | 1,683.12 |
|
Current Liabilities
|
1,342.80 | 15,430.30 | 5,884.79 | 1,805.78 | 23,591.58 |
|
Total Liabilities
|
6,317.22 | 56,576.70 | 27,754.83 | 4,323.87 | 1,08,407.20 |
Assets (₹ Cr)
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,373.25 | 26,891.10 | 20,096.89 | 420.16 | 44,135.45 |
|
Current Assets
|
3,823.28 | 29,732.20 | 7,956.27 | 3,230.14 | 69,266.58 |
|
Total Assets
|
6,317.22 | 56,576.70 | 27,754.83 | 4,323.87 | 1,08,407.20 |
|
Total Debt*
|
211.99 | 7,734.10 | 6,021.78 | 0.00 | 4,081.61 |
|
Net Current Assets
|
2,480.48 | 14,301.90 | 2,071.48 | 1,424.36 | 45,675.00 |
|
Contingent Liabilities
|
8.12 | 336.14 | 924.77 | 515.18 | 1,587.05 |
Cashflow (₹ Cr)
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
529.19 | 5,673.70 | 3,121.29 | 903.30 | 12,419.18 |
|
Cash Flow from Investing Activities
|
-428.92 | -6,549.30 | -196.42 | 396.98 | -11,344.05 |
|
Cash from Financing Activities
|
-167.92 | 829.00 | -2,952.69 | -737.08 | -2,512.55 |
|
Net Cash Inflow / Outflow
|
-67.65 | -46.60 | -27.82 | 563.20 | -1,437.42 |
Ratios
Profitability Ratios
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
ROCE (%)
|
32.67 | 13.75 | 13.24 | 66.79 | 19.11 |
|
ROE (%)
|
26.91 | 7.30 | 13.86 | 54.63 | 14.23 |
|
ROA (%)
|
20.88 | 4.93 | 7.79 | 30.04 | 10.10 |
|
EBIT Margin (%)
|
24.22 | 8.22 | 20.61 | 32.60 | 24.19 |
|
Net Margin (%)
|
19.70 | 8.03 | 14.32 | 26.40 | 17.23 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
25.01 | -3.53 | 13.53 | 12.12 | 12.13 |
|
EBIT Growth (%)
|
32.42 | -58.47 | 31.59 | 18.32 | 7.78 |
|
Net Profit Growth (%)
|
29.70 | -51.77 | 27.79 | 20.03 | 4.94 |
|
EPS Growth (%)
|
29.67 | -51.50 | 34.22 | 18.87 | 6.57 |
|
Book Value Growth (%)
|
19.52 | 12.99 | 13.74 | 16.12 | 15.72 |
Valuation Ratios
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Price / Earnings
|
32.83 | 40.84 | 43.56 | 38.47 | 34.57 |
|
Price / Book Value
|
8.53 | 2.95 | 5.82 | 17.30 | 4.76 |
|
Dividend Yield (%)
|
0.84 | 0.58 | 0.04 | 2.22 | 0.90 |
|
EV/EBITDA
|
24.31 | 23.67 | 26.08 | 28.74 | 22.15 |
|
Market Cap (₹ Cr)
|
35,015.54 | 1,04,763.81 | 82,801.75 | 38,682.23 | 4,21,639.92 |
Solvency Ratios
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.17 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.05 | 0.16 | 0.04 | -- | 0.05 |
|
Current Ratio
|
2.85 | 1.93 | 1.35 | 1.79 | 2.94 |
|
Quick Ratio
|
2.13 | 1.40 | 0.95 | 1.48 | 2.40 |
|
Interest Coverage
|
132.03 | 8.82 | 6.55 | 477.94 | 45.41 |
Operating Efficiency Ratios
| Ajanta Pharma | Dr. Reddy'S Labs | Mankind Pharma | Glaxosmithkline Pharma | Sun Pharmaceutical | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
29.98 | 30.64 | 14.17 | 8.16 | 28.89 |
|
Asset Turnover
|
1.03 | 0.59 | 0.53 | 1.09 | 0.56 |
|
Receivable days
|
49.07 | 103.79 | 39.93 | 24.45 | 89.14 |
|
Inventory Days
|
29.77 | 79.94 | 51.78 | 40.60 | 67.85 |
|
Payable days
|
183.00 | 84.78 | 111.46 | 172.70 | 213.72 |
|
Cash Conversion Cycle
|
-104.16 | 98.95 | -19.75 | -107.65 | -56.72 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
